Benzinga
26 Feb 2026, 19:19 UTC · 29w ago
Verdict
Headline leans bullish. We score NVAX +0.60 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Novavax's 2026 projected adjusted total revenue of $230 million to $270 million is significantly lower than the analyst consensus of $381.22 million.
More negative than 99% of claims this week
Novavax shifted to a profit in the fourth quarter with earnings of 11 cents per share, compared to a 51-cent loss a year ago.
Continue reading
5 related stories
More positive than 73% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
The company beat its 2025 cost-cutting targets and has introduced more aggressive expense goals for 2026 through 2028.
More positive than 85% of claims this week
Fourth-quarter revenue grew 67% year-over-year to $147 million.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company swung to a profit, beat cost-cutting targets, and saw a significant share price increase following positive quarterly earnings.
More positive than 45% of ticker scores this week
Mentioned positively in the context of Novavax achieving key milestones under their mutual agreement.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market Watch
5h ago
+12.1%
Price agrees with the score
$10.68 vs $9.53 close before publication (Feb 25) · not market-adjusted
NVAX chart →
